Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 10, Issue 6, Pages 955-965Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERA.10.63
Keywords
EGF receptor inhibition; gefitinib; IPASS; IRESSA (TM) Pan-Asia Study; non-small-cell lung cancer; targeted therapy
Categories
Funding
- AstraZeneca
Ask authors/readers for more resources
Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and have poor long-term prognosis. Gefitinib, a targeted therapy that prevents ATP binding in the tyrosine kinase domain of the EGF receptor, has been subject to comprehensive clinical development. A Phase III trial has demonstrated that gefitinib is superior to carboplatin/paclitaxel in terms of progression-free survival and objective response rate, as first-line treatment for pulmonary adenocarcinoma among never-smokers or former light smokers in East Asia (the IRESSA (TM) Pan-Asia Study), with the presence of an EGFR mutation being a strong predictor of the effect of gefitinib compared with carboplatin/paclitaxel. In this article, these results are discussed in the context of other recently reported studies of EGFR mutation-positive patients in both Asian and non-Asian countries. Furthermore, the clinical implications and future challenges for gefitinib are highlighted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available